板块复苏：2025年至今医药板块迎来复苏 从资本市场来看：医药板块经历了4年的调整期，2025年至今板块迎来复苏，截至2025年5月30日，医药 生物行业涨跌幅位居申万31个一级行业中第6位，累计上涨4.57%。医药持仓环比上升，但仍处于历史 中低位。 趋势展望：创新药和AI带来增量机会，左侧资产带来存量机会 智通财经APP获悉，国联民生证券发布研报称，创新药建议布局存量风险出清、增量产品进入放量期、 估值合理的传统药企以及研发基础扎实、产品具备出海竞争力、2025年有出海关键进展的创新药企。医 药AI建议布局在数据、硬件和服务领域具备AI要素禀赋、存量业务相对扎实的公司。左侧资产估值修 复建议关注存量风险可控、估值合理、需求稳健增长的左侧资产，主要集中在传统药企、CRO、骨 科、IVD、医疗服务等赛道。 国联民生证券主要观点如下： 从基本面来看：医药多个细分板块的景气度企稳向上。创新药出海案例增多，中国在全球创新药研发中 占据越来越重要的地位;传统药企逐渐走出存量业务困境，实现创新转型;CXO、消费医疗等赛道也慢慢 走上了温和复苏之路。 增量看空间，存量看结构：增量机会可能会来自于创新药和AI带来的潜在成长 ...

南都讯记者吕虹发自北京6月25日，记者从中国科协新闻发布会上获悉，第二十七届中国科协年会将于7 月1日至31日在北京集中举办，主题为"示踪科技前沿助力创新发展"。本届年会由1场主论坛、98场专题 论坛以及4场平行论坛组成，并设置发布、宣传与科普、展览展示与场景体验等版块，主论坛拟于7月6 日上午在中国科技会堂举行。 作为中国科协年会改革后的首次亮相，本届年会以"创新体制机制"为最大亮点，组织近70家全国学会会 同国家战略科技力量等，围绕国家"十五五"规划涉及的重大科技领域，聚焦其中的前沿、"非共识"科技 问题，推荐了近260个议题，以自下而上的方式凝聚科技工作者共识。本届年会首启了非共识议题征集 活动，动员98场专题论坛围绕研讨主题，提出能够触发相关领域学术理念突破、现有知识体系或权威论 断颠覆、研究方法与工具变革、数据解释或应用方向变化，可在学术界引发广泛讨论的非共识议题。经 专家评议，形成非共识议题清单，并将于年会结束时线上发布。 在活动安排上，主论坛将邀请潘建伟、谭天伟、李家彪、戴琼海、万建民等五位中国科协副主席和全国 学会负责人，围绕量子技术、生物制造(生物医药)、深海科技、人工智能、农业(育种)等主 ...

Core Viewpoint - The Daxing Biomedical Industry Base, known as "China Pharmaceutical Valley," is accelerating its development in the life and health industry, aiming for high-quality growth and international influence by 2025 [1][3][13]. Group 1: Industry Development - The life and health industry is a strategic emerging industry crucial for national security and public welfare, with Daxing District being a key area for its development in Beijing [3][4]. - The Daxing Biomedical Industry Base has expanded by 9.1 square kilometers, enhancing its capacity for industrial research and production, as well as supporting services [4]. - The base is set to strengthen its core industries, including vaccines, traditional Chinese medicine, and high-end medical devices, while also exploring new sectors like medical aesthetics and animal pharmaceuticals [7][13]. Group 2: Project Initiatives - Several high-impact biomedical projects are set to be established in the Daxing Biomedical Industry Base, including innovative drug development and antibody production [6]. - The second phase of the China Food and Drug Inspection Institute's project has commenced, significantly boosting the region's research and testing capabilities [5]. - The base is actively promoting the construction of a new campus for Capital Medical University, which will enhance research innovation and industry integration [4]. Group 3: Technological Integration - The Daxing Biomedical Industry Base is leveraging big data and artificial intelligence to enhance its service and digital capabilities across various sectors [8][10]. - The base is transitioning from a product-oriented approach to a service-oriented model, exemplified by the establishment of a new retail consumption model by Tongrentang Health [8]. - Advanced AI technologies are being integrated into drug research and development, marking a significant shift towards innovative pharmaceutical solutions [10]. Group 4: Policy and Support - The Daxing Biomedical Industry Base is implementing a "one-stop service platform" to optimize the business environment and support enterprises in accessing various policy benefits [12]. - The base has facilitated the application of over 50 projects for national and municipal policy support, enhancing the operational capabilities of more than 30 enterprises [12]. - The base is committed to fostering a collaborative ecosystem by establishing shared platforms for high-value instruments and equipment among research institutions [11].

从7月1日开始，全国学会将围绕数理化基础科学、生命健康（含医学）、地球科学（含深地深海）、生 态环境、制造科技、信息科技、先进材料、资源能源、农业科技（含食品）、空天科技等10个领域陆续 举办98场专题论坛。4场平行论坛包括2025中国科技期刊发展论坛、中国科技创新发展环境论坛、港澳 科技界服务国家科技创新座谈会、中国科协主席与青年科技人才见面会。 今年年会还将举办中国科协年会历史沿革展、中国科技会堂专家报告展、科技发展成就展等。此外，中 国科技会堂咖啡厅等区域将开展开放式学术交流与科技场景体验活动。（记者代小佩） 科技日报北京6月25日电 记者25日从中国科协举办的新闻发布会上获悉，第二十七届中国科协年会将于 7月1日—31日在北京举办，主题为"示踪科技前沿 助力创新发展"。此次年会由1场主论坛、98场专题论 坛以及4场平行论坛组成，并设置信息发布、宣传与科普、展览展示与场景体验等板块。 中国科协科学技术创新部副部长杨书宣介绍，本届年会主论坛拟于7月6日在中国科技会堂举行，届时将 邀请潘建伟、谭天伟、李家彪、戴琼海、万建民等五位中国科协副主席、全国学会负责人，围绕量子技 术、生物制造（生物医药）、深海科技、 ...

Core Viewpoint - The company is undergoing a significant change in control as it plans to issue shares to a specific entity, which will result in a new controlling shareholder and actual controller [1][2][5]. Group 1: Control Change Announcement - The company announced that its controlling shareholder, Jinan Licheng Holding Group Co., Ltd., is planning to issue shares to specific investors, potentially leading to a change in actual control [1][2]. - The stock was suspended from trading on June 23, 2025, and resumed trading on June 26, 2025, following the announcement [1]. Group 2: Share Issuance Details - The company signed a conditional share subscription agreement with Xiamen Jianxi, which will fully subscribe to the new shares issued [2][3]. - The company plans to issue up to 42,040,200 shares, raising a total of no more than 365.75 million yuan [2][4]. - After the issuance, Xiamen Jianxi will hold 23.08% of the company's total shares, making it the new controlling shareholder [2][5]. Group 3: Financial Implications - The funds raised from the share issuance will be used to supplement working capital and repay debts [4]. - Prior to the issuance, Xiamen Jianxi did not hold any shares in the company, and the issuance will result in a significant reduction of the current controlling shareholder's stake [5]. Group 4: Recent Financial Performance - In the first quarter of 2025, the company reported a revenue of 142.13 million yuan, a decrease of 12.40% year-on-year [6][7]. - The net profit attributable to shareholders was -2.66 million yuan, reflecting a decrease of 606.45% compared to the previous year [6][7]. - The net cash flow from operating activities was -40.24 million yuan, indicating a decline of 42.52% year-on-year [6][7].

Group 1: Brain-Computer Interface Standards - The National Standard for Non-Invasive Medical Devices Using Brain-Computer Interface Technology is open for public consultation, aiming to establish performance indicators and testing methods for such devices [1] - The standardization is expected to enhance international cooperation and improve regulatory efficiency, addressing the rapid development in the non-invasive neural modulation sector [1] Group 2: Pharmaceutical Industry Innovation - The head of the National Medical Products Administration emphasized the importance of supporting drug and medical device R&D innovation to strengthen China's pharmaceutical industry [2] - Key strategies include early intervention, tailored guidance for enterprises, and promoting international multi-center clinical trials to synchronize the development and approval of innovative drugs and devices [2][3] Group 3: Clinical Trials and Approvals - Shenzhou Cell announced that its product SCTB39G received approval for clinical trials in advanced solid tumors [4] - Hanyu Pharmaceutical's subsidiary received approval for the listing of the raw material drug Acetate Degarelix, which is used for treating advanced prostate cancer [6] Group 4: Market Expansion and IPOs - Kangzhe Pharmaceutical plans a secondary listing in Singapore, reflecting a trend of pharmaceutical companies expanding into Southeast Asian markets [7] - Lianya Pharmaceutical's IPO application has been accepted, focusing on complex drug formulations and high-end generic drugs [9] Group 5: Strategic Collaborations - Bayer and Tsinghua University signed a strategic cooperation agreement to enhance research in various medical fields, aiming to accelerate drug innovation [11][12] Group 6: Clinical Trial Developments - Fuhong Hanlin announced the first patient enrollment in a bridging clinical trial for its drug H, which is approved for first-line treatment of small cell lung cancer in multiple countries [13] Group 7: Corporate Leadership Changes - Fosun Pharma held a shareholder meeting to elect new board members, appointing Chen Yuqing as chairman and Liu Yi as CEO [14]

Group 1 - The event showcased 240 major scientific achievements, focusing on the urgent needs in key areas such as artificial intelligence, high-end equipment manufacturing, and advanced new materials in Guangxi [1][2] - A total of 25 projects reached cooperation intentions, with a total signed amount of 88.75 million yuan, including 21 key projects that were signed on-site [1] - 65 cutting-edge scientific achievements were selected for physical display, while 240 achievements were simultaneously released online, providing new ideas and technical support for the development of Guangxi's advantageous and characteristic industries [1] Group 2 - The event was co-hosted by the Guangxi Zhuang Autonomous Region Science and Technology Department and the Guangzhou Branch of the Chinese Academy of Sciences, themed "CAS Enters Guangxi, Creating a Future" [2] - The aim was to deepen the scientific and technological innovation cooperation between the Chinese Academy of Sciences and Guangxi, injecting more innovative vitality into the high-quality development of industries [2]

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its business operations and financial performance. Group 1: Main Business Operations - The company reported a total revenue of 2,253.67 million yuan from its research and experimental development sector in 2024, with a year-on-year growth of 32.41% in the front-end molecular building blocks and tool compounds business, generating 1,499.07 million yuan [1][4] - The product sales revenue in this segment was 1,363.90 million yuan, reflecting a 36.01% increase, while the gross profit margin stood at 63.74% [1][4] - The back-end raw materials and intermediates development business generated 754.61 million yuan, with a modest year-on-year growth of 2.49%, but product sales in this segment saw a decline of 30.45% [1][4] Group 2: Revenue and Profitability Analysis - Domestic and overseas business revenues were 1,391.69 million yuan and 861.99 million yuan respectively, with gross profit margins of 38.82% and 46.8% [1][4] - The company provided a detailed breakdown of its four business segments, including revenue, gross profit margins, and year-on-year changes, indicating a comprehensive analysis of market size and competitive landscape [1][4][6] Group 3: Market Trends and Growth Potential - The global pharmaceutical R&D expenditure is projected to grow at a rate of 4.2% annually, reaching 254 billion USD by 2026, which is expected to positively impact the life sciences reagent market [6][7] - The Chinese research reagent market has expanded from approximately 25 billion yuan in 2018 to about 48 billion yuan in 2022, with a compound annual growth rate of around 18% [6][7] - The global CDMO market is also on a growth trajectory, with expectations to reach 124.3 billion USD by 2025, indicating a robust demand for innovative drug development services [9][10] Group 4: Competitive Positioning - The company has established itself as a competitive player in the life sciences reagent sector, particularly in the molecular building blocks and tool compounds market, which is characterized by strong customization capabilities and a growing customer base [2][4] - The company’s tool compounds business is positioned favorably compared to peers, with higher revenue growth and gross profit margins, reflecting its strong international influence [11][12] - The company’s performance in the generic drug intermediates and raw materials sector aligns with industry trends, with a notable increase in the market for high-end pharmaceutical intermediates [13][14]

Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. maintains a stable credit rating of AA- with a positive outlook, reflecting steady revenue growth and an optimized business structure despite rising debt levels and increased sales expenses [4][6][8]. Financial Performance - Total assets increased from 64.17 billion in 2022 to 73.03 billion in 2025, while total liabilities rose from 17.85 billion to 29.22 billion during the same period [5][6]. - The company's net profit for Q1 2025 decreased by 54.36% year-on-year, primarily due to significant inventory impairment provisions and rising sales expenses [7][8]. - Revenue from the core brand series, Dikao, grew by 10.73% in 2024, contributing to a shift towards self-owned brands [6][19]. Business Structure and Strategy - The company acquired a 60.199% stake in Shanghai Baiyang Pharmaceutical for 880 million, extending its value chain into pharmaceutical manufacturing [6][10]. - The brand operation revenue and gross profit ratios increased to 68.68% and 92.84%, respectively, as the company reduced its reliance on wholesale distribution [5][19]. - The company is transitioning from a focus on agency brands to self-owned brands, with ongoing investments in innovative pharmaceutical products [19][20]. Market Environment - The pharmaceutical industry is experiencing a shift towards digitalization and consolidation, with increasing competition among large-scale distributors and retail pharmacies [12][14]. - The impact of healthcare reform policies is stabilizing, but the industry still faces challenges related to profitability and market competition [14][15]. - The demand for specialized brand promotion and operational services is rising, driven by the need for personalized marketing strategies in the pharmaceutical sector [15][16]. Risks and Challenges - The company faces increased debt pressure, with total debt rising by 56.44% year-on-year, leading to a debt-to-capital ratio exceeding 60% [7][8]. - The concentration risk in brand operations is notable, as the Dikao series accounted for 25.95% of total revenue in 2024, raising concerns about market fluctuations [8][20]. - The company must navigate potential disruptions in brand partnerships due to changes in global product rights by upstream multinational pharmaceutical companies [8][19].

Group 1 - The Chengdu-Chongqing economic circle expert group conducted on-site research and discussions in Chongqing's Bishan District, focusing on nine key projects across six sectors including health management, biopharmaceuticals, medical devices, and intelligent manufacturing [1] - Bishan District is actively exploring a new model of integrated development between traditional Chinese medicine and cultural tourism, promoting the organic integration of traditional medical culture with modern health lifestyles [1] - The district is advancing the innovation development of the life sciences industry, leveraging the construction of the China-Singapore Life Science City to build an innovation chain for the life and health industry [1] Group 2 - The Deputy Secretary of the Bishan District Committee and District Governor invited experts to establish innovation initiatives in Bishan and to translate research outcomes into practical applications [2] - Bishan District aims to deepen the construction of expert think tanks and establish a regular consultation mechanism, enhancing the "government-industry-university-research-application" collaborative system to accelerate the gathering of innovative elements [2] - The Chengdu-Chongqing economic circle expert group serves as a cross-regional expert service platform, having provided intellectual services to over 60 cities and districts in the region over the past five years [2]